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Peritoneal Tuberculosis
After Imatinib Therapy
I matinib mesylate, a selective inhibitor of the BCR-ABL tyrosine kinase gene, is now a standard therapyinpatientswith chronicmyeloid leukemia (CML)and
gastrointestinal stromal tumor (GIST). Recent studies have
shown that imatinib alters T-cell–mediated immune re-
sponses,1-4 raising the possibility of opportunistic infec-
tions associated with imatinib therapy. So far, few epide-
miological data are available to support this hypothesis.
We report herein a case of peritoneal tuberculosis (TB)
following 4 months of imatinib therapy for CML.
Report of a Case. A 37-year-old Swiss-born man was di-
agnosed as having BCR-ABL–positive CML, and ima-
tinib mesylate therapy was initiated (400 mg/d). One
month later, the imatinib dosage was reduced owing to
an elevation in transaminase (3 times the upper limit of
normal) and alkaline phosphatase (4 times the upper limit
of normal) levels. Serologic test results for human im-
munodeficiency virus and hepatitis A, B, andC viruswere
negative, and the abnormal liver test results were attrib-
uted to imatinib therapy. Four months later, the ima-
tinib mesylate dosage was again increased to 400 mg/d.
One week later, the patient developed abdominal pain,
anorexia, and nausea. Abdominal computed tomogra-
phy revealed ascites, hepatosplenomegaly, and diffuse
infiltration of mesenteric fat. An analysis of ascitic fluid
revealed a white blood cell count of 1100/µL (50% lym-
phocytes) (to convert to109/L,multiply by 0.001). Stan-
dard bacterial cultures remained sterile. Findings from
aZiehl-Neelsen stain andmycobacterial culturewerenega-
tive for organisms. Imatinib therapy was discontinued.
Exploratory laparoscopy revealed extensive peritonitis,
and peritoneal biopsy specimens demonstrated granu-
lomatous inflammation, with a negative Ziehl-Neelsen
stain result but a positive polymerase chain reaction re-
sult for Mycobacterium tuberculosis complex and posi-
tive cultures for M tuberculosis. The patient had no his-
tory of travel to a TB endemic country, prior TB exposure,
homelessness, or substance use. A chest radiograph show
no abnormalities. The initiationof antituberculous therapy
was followed by clinical improvement. Imatinib therapy
was not restarted because of a concern for pharmaco-
logical interaction with rifampin. After 6 months of an-
tituberculous therapy, the patient underwent a hemo-
poietic stemcell transplantationwithout further infectious
complications.
At the time of TB diagnosis, 1 month after imatinib
therapy discontinuation, there was global lymphopenia
(CD3, CD4, and CD8 cells: 190 [76% {percentage of
total lymphocytes}], 155 [62%], and 39 [16%] cells/µL,
respectively) and no evidence of blast transformation of
CML. After 2 months of antituberculous therapy, lym-
phopenia was still present but less pronounced (CD3,
CD4, and CD8 cells: 846 [92%], 619 [67%], and 222
[24%] cells/µL, respectively).
Comment. To our knowledge, this is the second report
of TB reactivation in association with imatinib therapy.
The incidence of TB in Switzerland is low (10 per
100 000 population per year), and the patient had no his-
tory of TB exposure. Global lymphopenia might have fa-
cilitated TB reactivation, but TB itself may induce tran-
sient lymphopenia.5 In fact, lymphocyte counts rose to
subnormal levels after the initiation of antituberculous
therapy. The increased incidence of herpes zoster6 and
previous cases of pulmonary nocardiosis,7 pulmonaryTB,8
and fungal pneumonia9 raise the possibility of opportu-
nistic infections associated with imatinib therapy, but
more data are needed. It might be prudent to investigate
the presence of latent TB (by purified protein derivative
skin testing or interferon- release assay) before the ini-
tiation of imatinib therapy.
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Underdiagnosis of Obesity in Adults
in US Outpatient Settings
O besity affects nearly 32%—more than 60 mil-lion—American adults.1 The obesity epidemicimposes an enormous cost on the nation’s
health2 and economy.3 Evidence-based clinical guide-
lines recommend that treatment for obesity incorpo-
rates a 2-step process: assessment andmanagement.4 Rou-
tine screening and accurate diagnosis are among the first
steps leading to proper treatment. However, research on
obesity screening and diagnosis in US outpatient set-
tings is limited.
Methods.Weexamined the rates of obesity screening and
diagnosis in a nationally representative sample of visits
by patients 18 years and older to private physician of-
fices and hospital outpatient departments across the
United States. Data were obtained from the 2005 Na-
tional Ambulatory Medical Care Surveys conducted by
the National Center for Health Statistics (NCHS) (http:
//www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm [ac-
cessed July 23, 2008]). Patient, physician, and clinical
information is collected at each randomly selected visit
and is recorded onNCHS standard patient record forms.
Measurements of height and weight were captured for
the first time in 2005. Body mass index (BMI) (calcu-
lated as weight in kilograms divided by height in meters
squared) and obesity were defined according to ac-
cepted standards.4 Physician diagnoses were docu-
mented using open-ended responses for (up to 3) visit
diagnoses, whichwere later coded byNCHS staff accord-
ing to the International Classification of Diseases, Ninth
Revision, Clinical Modification and check boxes for a pre-
specified list of current medical problems, one of which
was obesity, regardless of visit diagnoses. The unit of
analysiswas the patient visit. National estimateswere gen-
erated using the SURVEYMEANS procedure (version
9.1.3; SAS Institute, Cary, North Carolina) for the num-
ber and proportion of patient visits, including 95% con-
fidence intervals (CIs), by taking into account the sam-
pling weights and multistage-stratified probability
sampling designs of the surveys.
Results. In 2005, American adults 18 years and older
made an estimated total of 845 million outpatient vis-
its (95% CI, 757 million–932 million). Measurements
were recorded during 42% (95% CI, 39%-46%) of total
visits for height, 65% (95% CI, 62%-68%) for weight,
and 41% (95% CI, 37%-45%) for both height and
weight. Of the visits for preventive care only, the cor-
responding rates were 52% (95% CI, 46%-58%), 75%
(95% CI, 71%-80%), and 51% (95% CI, 46%-57%),
respectively. Of the total visits in which BMI was
obtainable, 37% (95% CI, 35%-40%) were for patients
with a BMI of 30.0 or greater.
Only 29% (95% CI, 25%-32%) of visits by patients
who were obese according to their BMI had a docu-
mented diagnosis of obesity (Figure). The proportion
of visits during which obesity was diagnosed was 19%
(95% CI, 15%-22%) for patients whose BMI was
between 30.0 and 34.9, 32% (95% CI, 26%-38%) for
those whose BMI was between 35.0 and 39.9, and 50%
(95% CI, 43%-57%) for those whose BMI was 40.0 or
greater. Obesity was diagnosed in less than 2% of visits
by patients whose BMI was less than 30.0. Owing to
the underreporting of clinical obesity, the agreement
between obesity defined by BMI and that by physician
diagnosis was low (=0.3).
Comment. These results indicate that obesity is under-
appreciated in clinical practice throughout the United
States. Health care providers often fail to obtain needed
biophysical patient data and do not clinically identify obe-
sity even when data that are obtained suggest this con-
dition. Barriers to obesity screening and diagnosis are
likely multiple andmay involve system, health care pro-
vider, and patient factors, including but not limited to,
the lack of infrastructure to meet the needs of obese pa-
tients, lack of time for preventive care, lack of health care
provider skills or financial incentives to address obe-
sity, health care provider or patient concerns aboutweight
stigma, and antifat bias by health care providers.5,6 Obe-
sity is a complex chronic condition, and health care pro-
viders have an important role in preventing, identify-
ing, and managing obesity.4 Body mass index and waist
circumference are simple, validatedmeasures of body fat
that provide a reliable prediction of disease risk. Re-
search aimed at determining the barriers to optimal health
care for obese patients will guide the development of in-
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Figure. Association of physician-diagnosed obesity with clinically measured
body mass index (BMI) (calculated as weight in kilograms divided by height
in meters squared). Error bars indicate 95% confidence intervals.
(REPRINTED) ARCH INTERN MED/VOL 169 (NO. 3), FEB 9, 2009 WWW.ARCHINTERNMED.COM
313
©2009 American Medical Association. All rights reserved.
